NCT05606341View on ClinicalTrials.gov

Innate Immunity Stimulation Via TLR9 in Early AD

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 13, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Mild Cognitive ImpairmentAlzheimer Dementia
Interventions
DRUG

CpG1018

"0.1 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."

DRUG

CpG1018

"0.25 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."

DRUG

CpG1018

"0.5 mg/kg dose administered via subcutaneous injection.~TLR9 agonist supplied by Dynavax Technologies Inc."

DRUG

Placebo

Sterile saline injection supplied by the NYU Investigational Pharmacy.

Trial Locations (1)

10016

RECRUITING

NYU Langone Health, New York

All Listed Sponsors
collaborator

Alzheimer's Association

OTHER

lead

NYU Langone Health

OTHER